JP6987786B2 - がんの進化の検出および診断 - Google Patents

がんの進化の検出および診断 Download PDF

Info

Publication number
JP6987786B2
JP6987786B2 JP2018559686A JP2018559686A JP6987786B2 JP 6987786 B2 JP6987786 B2 JP 6987786B2 JP 2018559686 A JP2018559686 A JP 2018559686A JP 2018559686 A JP2018559686 A JP 2018559686A JP 6987786 B2 JP6987786 B2 JP 6987786B2
Authority
JP
Japan
Prior art keywords
state
subject
information
time point
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018559686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512823A (ja
JP2019512823A5 (de
Inventor
ヘルミー エルトーキー，
アミルアリ タラサズ，
Original Assignee
ガーダント ヘルス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ガーダント ヘルス， インコーポレイテッド filed Critical ガーダント ヘルス， インコーポレイテッド
Publication of JP2019512823A publication Critical patent/JP2019512823A/ja
Publication of JP2019512823A5 publication Critical patent/JP2019512823A5/ja
Priority to JP2021195284A priority Critical patent/JP7487163B2/ja
Application granted granted Critical
Publication of JP6987786B2 publication Critical patent/JP6987786B2/ja
Priority to JP2024075758A priority patent/JP7805394B2/ja
Priority to JP2026003614A priority patent/JP2026065085A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Primary Health Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018559686A 2016-02-02 2017-02-02 がんの進化の検出および診断 Active JP6987786B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021195284A JP7487163B2 (ja) 2016-02-02 2021-12-01 がんの進化の検出および診断
JP2024075758A JP7805394B2 (ja) 2016-02-02 2024-05-08 がんの進化の検出および診断
JP2026003614A JP2026065085A (ja) 2016-02-02 2026-01-13 がんの進化の検出および診断

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662290375P 2016-02-02 2016-02-02
US62/290,375 2016-02-02
PCT/US2017/016295 WO2017136603A1 (en) 2016-02-02 2017-02-02 Cancer evolution detection and diagnostic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021195284A Division JP7487163B2 (ja) 2016-02-02 2021-12-01 がんの進化の検出および診断

Publications (3)

Publication Number Publication Date
JP2019512823A JP2019512823A (ja) 2019-05-16
JP2019512823A5 JP2019512823A5 (de) 2020-03-05
JP6987786B2 true JP6987786B2 (ja) 2022-01-05

Family

ID=59500171

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018559686A Active JP6987786B2 (ja) 2016-02-02 2017-02-02 がんの進化の検出および診断
JP2021195284A Active JP7487163B2 (ja) 2016-02-02 2021-12-01 がんの進化の検出および診断
JP2024075758A Active JP7805394B2 (ja) 2016-02-02 2024-05-08 がんの進化の検出および診断
JP2026003614A Pending JP2026065085A (ja) 2016-02-02 2026-01-13 がんの進化の検出および診断

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021195284A Active JP7487163B2 (ja) 2016-02-02 2021-12-01 がんの進化の検出および診断
JP2024075758A Active JP7805394B2 (ja) 2016-02-02 2024-05-08 がんの進化の検出および診断
JP2026003614A Pending JP2026065085A (ja) 2016-02-02 2026-01-13 がんの進化の検出および診断

Country Status (8)

Country Link
US (6) US11335463B2 (de)
EP (2) EP4779643A2 (de)
JP (4) JP6987786B2 (de)
CN (2) CN109072309B (de)
CA (1) CA3013366A1 (de)
ES (1) ES3071648T3 (de)
SG (1) SG11201806609TA (de)
WO (1) WO2017136603A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3246416B1 (de) 2011-04-15 2024-06-05 The Johns Hopkins University Sicheres sortierungssystem
WO2014070462A1 (en) 2012-10-29 2014-05-08 The Johns Hopkins University Papanicolaou test for ovarian and endometrial cancers
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
EP4779643A2 (de) 2016-02-02 2026-07-22 Guardant Health, Inc. Nachweis und diagnose von krebsentwicklung
EP3792922A1 (de) 2016-09-30 2021-03-17 Guardant Health, Inc. Verfahren zur mehrauflösungsanalyse von zellfreien nukleinsäuren
US10353937B2 (en) * 2017-04-17 2019-07-16 Mammoth Medical, Llc Automated characterization-vector based recommendation
KR20250047324A (ko) 2017-08-07 2025-04-03 더 존스 홉킨스 유니버시티 암을 평가하고 치료하기 위한 방법 및 재료
EP3697946A4 (de) * 2017-10-17 2021-07-14 President And Fellows Of Harvard College Verfahren und systeme zur detektion somatischer strukturvarianten
CN111542616A (zh) * 2017-11-03 2020-08-14 夸登特健康公司 脱氨引起的序列错误的纠正
US11972841B2 (en) 2017-12-18 2024-04-30 Personal Genome Diagnostics Inc. Machine learning system and method for somatic mutation discovery
CA3302676A1 (en) 2018-04-02 2026-05-13 Grail, Inc. Methylation markers and targeted methylation probe panels
EP3856903A4 (de) 2018-09-27 2022-07-27 Grail, LLC Methylierungsmarker und gezieltes methylierungssondenpaneel
CN111382756B (zh) * 2018-12-28 2023-06-02 台湾中国医药大学附设医院 影像电脑辅助直肠癌治疗反应预测系统及方法
EP4567131A3 (de) 2019-01-31 2025-09-03 Guardant Health, Inc. Zusammensetzungen und verfahren zur isolierung von zellfreier dna
AU2020378435B2 (en) * 2019-11-06 2026-07-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11586964B2 (en) * 2020-01-30 2023-02-21 Dell Products L.P. Device component management using deep learning techniques
WO2021163546A1 (en) 2020-02-14 2021-08-19 The Johns Hopkins University Methods and materials for assessing nucleic acids
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US20230154618A1 (en) * 2021-11-16 2023-05-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bayesian Approach For Tumor Forecasting
JP2024000182A (ja) * 2022-06-20 2024-01-05 キヤノンメディカルシステムズ株式会社 治療計画支援装置、治療計画支援方法、及びプログラム
CN116363647B (zh) * 2023-03-29 2026-05-01 北京透彻未来科技有限公司 基于深度语义分割网络的肺癌病理组织分型系统

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5897600A (en) 1999-06-29 2001-01-31 Intercet, Ltd. Human cancer virtual simulation system
WO2004038376A2 (en) * 2002-10-24 2004-05-06 Duke University Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
US7943306B2 (en) * 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP2087140A2 (de) * 2006-11-13 2009-08-12 Source Precision Medicine, Inc. Genexpressionsprofilierung zur identifikation, überwachung und behandlung von lungenkarzinom
US20100255470A1 (en) * 2007-04-05 2010-10-07 Source Percision Medicine, Inc. D/B/A Source Mdx Gene Expression Profiling for Identification, Monitoring and Treatment of Breast Cancer
WO2009036388A2 (en) 2007-09-14 2009-03-19 University Of South Florida Gene signature for the prediction of radiation therapy response
EP2188630A4 (de) 2007-10-02 2010-11-03 Univ Rochester Methoden und kompositionen in bezug auf synergistische antworten auf onkogene mutationen
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
WO2009138909A1 (en) 2008-05-12 2009-11-19 Koninklijke Philips Electronics N.V. A medical analysis system
EP3216874A1 (de) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Verfahren zum stratifizieren und annotieren der behandlungsoptionen eines krebsmedikaments
CN102858995B (zh) 2009-09-10 2016-10-26 森特瑞隆技术控股公司 靶向测序方法
AU2011242990B2 (en) 2010-04-19 2015-02-12 Biomarker Strategies, Llc. Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
SG10201505723UA (en) * 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
CA3081061C (en) * 2010-07-27 2023-01-03 Genomic Health, Inc. Method for using expression of klk2 to determine prognosis of prostate cancer
US8548937B2 (en) 2010-08-17 2013-10-01 Wisercare Llc Medical care treatment decision support system
WO2012079059A2 (en) * 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis
US20140038197A1 (en) 2011-01-07 2014-02-06 Thomas Jefferson University System for and method of determining cancer prognosis and predicting response to therapy
US9260753B2 (en) 2011-03-24 2016-02-16 President And Fellows Of Harvard College Single cell nucleic acid detection and analysis
EP2613278A2 (de) * 2011-12-05 2013-07-10 Koninklijke Philips Electronics N.V. Retroaktive Gewinnung von klinisch relevanten Informationen aus Patientensequenzierungsdaten zur Unterstützung bei klinischen Entscheidungen
WO2013142389A1 (en) 2012-03-20 2013-09-26 University Of Washington Through Its Center For Commercialization Methods of lowering the error rate of massively parallel dna sequencing using duplex consensus sequencing
US11261494B2 (en) * 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
PL2893040T3 (pl) * 2012-09-04 2019-05-31 Guardant Health Inc Sposoby wykrywania rzadkich mutacji i wariantu liczby kopii
HUE053822T2 (hu) 2012-09-20 2021-07-28 Univ Hong Kong Chinese Nem invazív módszer daganat metilom meghatározása plazmából
US20140088989A1 (en) 2012-09-27 2014-03-27 Balaji Krishnapuram Rapid Learning Community for Predictive Models of Medical Knowledge
ES2980689T3 (es) 2013-03-15 2024-10-02 Guardant Health Inc Métodos para la secuenciación de polinucleótidos libres de células
CA2914026A1 (en) * 2013-06-04 2014-12-11 University Of Miami Assays, methods and kits for analyzing sensitivity and resistance to anti-cancer drugs, predicting a cancer patient's prognosis, and personalized treatment strategies
WO2015183026A1 (ko) 2014-05-28 2015-12-03 주식회사 툴젠 불활성화된 표적 특이적 뉴클레아제를 이용한 표적 dna의 분리 방법
WO2016040901A1 (en) 2014-09-12 2016-03-17 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acids
HK1245444A1 (zh) 2014-12-17 2018-08-24 Foundation Medicine, Inc. 计算机执行系统及识别类似患者的方法
EP3288455B1 (de) 2015-05-01 2023-12-06 Guardant Health, Inc. Diagnoseverfahren
JP6991134B2 (ja) 2015-10-09 2022-01-12 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａを使用する集団ベースの処置レコメンダ
EP4779643A2 (de) 2016-02-02 2026-07-22 Guardant Health, Inc. Nachweis und diagnose von krebsentwicklung

Also Published As

Publication number Publication date
US11996202B2 (en) 2024-05-28
JP2024112831A (ja) 2024-08-21
US20240274299A1 (en) 2024-08-15
JP2022028907A (ja) 2022-02-16
US12597524B2 (en) 2026-04-07
US11335463B2 (en) 2022-05-17
US11282610B2 (en) 2022-03-22
US20250329469A1 (en) 2025-10-23
JP2019512823A (ja) 2019-05-16
JP2026065085A (ja) 2026-04-14
EP3411505A1 (de) 2018-12-12
JP7487163B2 (ja) 2024-05-20
WO2017136603A1 (en) 2017-08-10
JP7805394B2 (ja) 2026-01-23
CN109072309A (zh) 2018-12-21
CN116640847A (zh) 2023-08-25
EP3411505B1 (de) 2026-04-08
ES3071648T3 (en) 2026-06-24
US11621083B2 (en) 2023-04-04
EP3411505A4 (de) 2020-01-15
US20210050072A1 (en) 2021-02-18
EP4779643A2 (de) 2026-07-22
US20230197284A1 (en) 2023-06-22
CN109072309B (zh) 2023-05-16
US20190005194A1 (en) 2019-01-03
CA3013366A1 (en) 2017-08-10
SG11201806609TA (en) 2018-09-27
EP3411505C0 (de) 2026-04-08
US20220359085A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
JP7805394B2 (ja) がんの進化の検出および診断
JP7689557B2 (ja) 相同組換え欠損を推定するための統合された機械学習フレームワーク
EP4008005B1 (de) Verfahren und systeme zum nachweis von mikrosatelliteninstabilität von krebs in einem flüssigen biopsietest
JP7458360B2 (ja) 疾患細胞不均一性を示す疾患の検出および処置、ならびに通信試験結果のためのシステムおよび方法
ES2989374T3 (es) Sistemas y procedimientos para predecir el estado de deficiencia de recombinación homóloga de una muestra
US20250137063A1 (en) Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
WO2022120076A1 (en) Clinical classifiers and genomic classifiers and uses thereof
Peng Integrative analysis of genomic aberrations in cancer and xenograft Models

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210818

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211201

R150 Certificate of patent or registration of utility model

Ref document number: 6987786

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250